The European Treatment Outcome Study (EUTOS) investigated the treatment and treatment outcome of patients with chronic myeloid leukaemia (CML). Data…
Browsing: Acute Lymphoblastic Leukemia
In a phase 1b, open-label, dose-escalation, multicentre study of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the combination…
ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, Consultant Medical Oncologist at The…
RAMASWAMY GOVINDAN, MD of the Washington University School of Medicine discusses Novel immune checkpoint inhibitors
SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University talks about the CheckMate 057 trial in non-squamous and…
SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University discusses MET exon 14 splice variants is the oncogenic…
SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University discusses the Future for PD pathway inhibitors in NSCLC
SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University discusses AZD9291 for T790M mutant EGFR is well tolerated.
LECIA SEQUIST, MD of Massachusetts General Hospital discusses TIGER X – Rociletinib for T790M EGFR mutations.
LECIA SEQUIST, MD of Massachusetts General Hospital answers the question How does Rociletinib differ from 1st generations EGFR TKIs?
LECIA SEQUIST, MD of Massachusetts General Hospital discusses ALK inhibitor Alectinib for NSCLC
This was my interview with Dr. Petros Grivas, GU medical oncologist from the Cleveland Clinic at the 2015 ASCO Annual…
In the phase 3 NCCTG N0574 (Alliance) trial, patients with 1 to 3 small brain metastases were randomised to receive…
A phase 3, randomised controlled trial showed that elective neck dissection improved overall survival by 12.5% and reduced risk of…
Data from the Childhood Cancer Survivor Study (CCSS), a retrospective cohort study of children diagnosed with cancer from 19701999 at…
The randomised, double-blind, phase 3 CheckMate 067 trial showed that nivolumab alone or nivolumab plus ipilimumab significantly improved progression-free survival…
LECIA SEQUIST, MD of Massachusetts General Hospital discusses LUX-Lung 8 trial and the role of EGFR inhibitors in Squamous Cell…
RAMASWAMY GOVINDAN, MD of the Washington University School of Medicine answers the question Will immunotherapy combination regimens be both beneficial…
RAMASWAMY GOVINDAN, MD of the Washington University School of Medicine discusses the role of systemic adjuvant therapy for resected T2N0…
DAVID ROSS CAMIDGE, MD, PHD discusses what causes mechanism resistance to Rociletinib and AZD929
A phase II trial suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma.…
Interim analysis of a phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy…
Findings from the PERSIST-1 study of patients with myelofibrosis suggest that pacritinib is significantly more effective than best available therapy…
An interim analysis of a large phase III study suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes…
DAVID ROSS CAMIDGE, MD, PHD, of the University of Colorado Denver answers the question what is the future for PD…
DAVID ROSS CAMIDGE, MD, PHD, of the University of Colorado Denver discusses the novel investigational agents for crizotinib resistant ALK-positive…
DAVID ROSS CAMIDGE, MD, PHD, of University of Colorado Denver discusses the role of T790M mutations in resistance to first…
This was my discussion at the ASCO Annual Meeting June 1, 2015 with Dr. Petros Grivas, medical oncologist specializing in…
Findings from a phase I/II study suggest that nivolumab is safe and effective in advanced liver cancer. Based on the…
Findings from a randomised phase III study indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous,…
Dr. Mark Kris, MD of Memorial Sloan Kettering discusses the role of MET in NSCLC and why earlier TKIs and…
Dr. Mark Kris of Memorial Sloan Kettering discusses phase II study of cabozantinib in RET rearranged NSCLC at the annual…
This was my interview with Dr. Alok Khorana of the Cleveland Clinic at the ASCO Annual Meeting on May 30,…
This is my conversation with Dr. Alok Khorana, Director of the GI Malignancy Program at the Cleveland Clinic. Dr. Khorana…
Dr. Mark Kris, MD or Memorial Sloan Kettering discuss the role of BRAF mutations in NSCLC and the potential treatment…
Dr. Mark Kris, MD of Memorial Sloan Kettering discusses the Lung Cancer Mutation Consortium and the role of Next Generation…
At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Eleni Efstathiou (The University of Texas MD Anderson Cancer…
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany) summarises…
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany)…
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Catherine Kelly (Mater Misericordiae University Hospital, Dublin, Ireland) reviews…
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany) describes…
Michael Kolodziej, MD, National Medical Director, Oncology Strategies, Aetna, Inc. talks about Next Steps in Oncology Payment Reform for Established…
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany)…
Roberta L. Buell, Principal, OnPoint Oncology, LLC discusses the Top 2015 Reimbursement Issues & ICD-10 Update from the Coding Mistress
Robert Baird Jr., RN, MSA, Chief Executive Officer, Dayton Physicians Network discusses Payment Reform for Established Provider & Payer Teams
David Eagle discusses what Are the Key Cost Drivers of Cancer Care moving forward at the COA meeting in Orlando
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Catherine Kelly (Mater Misericordiae University Hospital, Dublin, Ireland) reviews…
James W. Hodge, PhD, MBA, Investigator, Laboratory of Tumor Immunology & Biology, Center for Cancer Research, National Cancer Center talks…
Phil Johnson, MS, RPh, Director of Pharmacy (Retired), Moffitt Cancer Center talks about Biosimilar Overview: Opportunities & Issues